Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in acute myeloid leukemia (AML), including recent drug approvals after numerous years of testing and our increasing understanding of the pathophysiology of this disease. This interview took place at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, in Lisbon, Portugal.
Changes in the AML treatment landscape
